Generic Firms Fear 'New Lifecycle Management Tool' From FDA Pill Size Guidance
This article was originally published in The Pink Sheet Daily
Executive Summary
Final guidance excludes attachment on capsules but otherwise is virtually identical to draft; GPhA had argued for flexibility in product design to avoid brand patents.
You may also be interested in...
Drug GMP and CMC Updates In Brief: Guidance Advances on Several Fronts
The US FDA revised two drug good manufacturing practice inspection programs in its compliance manual to reflect certain ICH guidance documents, efforts to control nitrosamine impurities and the use of inspection alternatives for evaluating facilities. Plus more recent developments in GMP and CMC compliance.
FDA Rejects Generic Tablets Larger Than Brand Citing Safety And Efficacy Concerns
FDA denies ANDAs for one product because the generic tablet size is larger than the brand; the agency plans to release a draft guidance on generic equivalency to the reference listed drug in size, taste and smell.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.